article
CD24 emerges as the next macrophage checkpoint
With CD47 therapies constrained by safety, attention is turning to CD24 as a macrophage checkpoint target. Pheast’s PHST001 has now entered the clinic.
List view / Grid view
Checkpoint receptors
news
New CAR T therapy targets solid tumours safely and effectively
USC researchers have engineered CAR T cells to deliver a dual protein therapy that targets solid tumours – offering hope for cancers previously resistant to treatment.
article
How to select the optimal bispecific antibody format for therapeutic success
Choosing the right bispecific antibody format can make or break your therapy’s success. This article explores how format impacts function, manufacturability and development strategy - helping you make the best choice from the start.
news
BCG alters bone marrow to strengthen anti-cancer response
A new study reveals that BCG, a decades-old bladder cancer treatment, reprograms the immune system at the bone marrow level, offering a new perspective into how this immunotherapy boosts the body’s defence against cancer.
news
Scientists develop immunotherapy to disarm fat-fuelled tumours
A new study reveals how tumours hijack fat metabolism to suppress immune responses - and how a novel antibody, PLT012, may reverse this effect, offering new hope for treating immunotherapy-resistant cancers.
webinar
Reprogramming immunity: designing smarter checkpoint receptor agonists
19 March 2025 | By Eurofins DiscoverX
Join Dr Daniela Cipolletta from Seismic Therapeutic to discover how FcγRIIb clustering enabled the discovery of S-4321, a low-affinity PD-1 agonist that restores immune balance by engaging multiple inhibitory pathways.
